title: Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome.
abstract: Posaconazole is a broad-spectrum triazole antifungal available as an oral suspension. Pharmacokinetic data showed a high variability of plasma posaconazole concentrations (PPCs) in patients, suggesting a potential interest in drug monitoring. The aim of our prospective study was to measure the PPCs in prophylactically treated patients to evaluate the impact of different factors on these concentrations. In 40 patients treated prophylactically with posaconazole for acute myeloid leukemia or myelodysplastic syndrome between February 2009 and August 2010, PPCs were measured at day 7 of treatment and then twice weekly. Demographic data, clinical data (including gastrointestinal disorders, comedications, and treatment compliance), caloric and fat intake, and biological data were collected and evaluated. We obtained 275 measurements of PPCs, with a median of 430 ng/ml. PPCs were significantly lower in patients with mucositis (P < 0.001), nausea (P = 0.03), diarrhea (P = 0.03), or vomiting (P = 0.05). PPCs were higher in patients with a higher caloric intake (P = 0.02), while the proportion of fat intake had no influence on PPCs (P = 0.84). The concomitant use of proton pump inhibitors decreased the PPCs (P = 0.02), while the use of tacrolimus increased the PPC (P = 0.03). In the multivariate analysis, the factors influencing the PPCs independently were the concomitant use of tacrolimus (P < 0.001), the presence of mucositis (P = 0.01), and food intake (P = 0.02). Our study confirmed the high variability of posaconazole bioavailability and showed the significant influence of gastrointestinal disorders, food intake, and concomitant medication on the PPCs. However, the optimal PPCs still remain to be defined and correlated with clinical efficacy.
authors.affiliation: Department of Clinical Hematology, Institute J. Bordet, Brussels, Belgium. mvaes@ulb.ac.be
authors.forename: M
authors.initials: M
authors.lastname: Vaes
authors.forename: M
authors.initials: M
authors.lastname: Hites
authors.forename: F
authors.initials: F
authors.lastname: Cotton
authors.forename: A M
authors.initials: AM
authors.lastname: Bourguignon
authors.forename: M
authors.initials: M
authors.lastname: Csergö
authors.forename: C
authors.initials: C
authors.lastname: Rasson
authors.forename: L
authors.initials: L
authors.lastname: Ameye
authors.forename: D
authors.initials: D
authors.lastname: Bron
authors.forename: F
authors.initials: F
authors.lastname: Jacobs
authors.forename: M
authors.initials: M
authors.lastname: Aoun
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D016903:Drug Monitoring; D005260:Female; D018565:Food-Drug Interactions; D005767:Gastrointestinal Diseases / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009190:Myelodysplastic Syndromes / Q000378:metabolism*; D011446:Prospective Studies; D013056:Spectrophotometry, Ultraviolet; D016559:Tacrolimus / Q000009:adverse effects; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D014230:Triazoles; C101425:posaconazole; D016559:Tacrolimus